Compare · AXGN vs PRKS
AXGN vs PRKS
Side-by-side comparison of Axogen Inc. (AXGN) and United Parks & Resorts Inc. (PRKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and PRKS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.09B, about 1.4x PRKS ($1.48B).
- PRKS has been more active in the news (13 items in the past 4 weeks vs 6 for AXGN).
- AXGN has more recent analyst coverage (11 ratings vs 8 for PRKS).
- Company
- Axogen Inc.
- United Parks & Resorts Inc.
- Price
- -
- -
- Market cap
- $2.09B
- $1.48B
- 1M return
- -23.49%
- -
- 1Y return
- +108.70%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 6
- 13
- Recent ratings
- 11
- 8
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Director Hartnett Timothy was granted 2,641 shares, increasing direct ownership by 3% to 84,019 units (SEC Form 4)
- Director Schaefer Kimberly was granted 602 shares, increasing direct ownership by 1% to 43,342 units (SEC Form 4)
- Director Narang Neha Jogani was granted 1,204 shares, increasing direct ownership by 2% to 58,580 units (SEC Form 4)
- Director Lipman Nathaniel was granted 301 shares, increasing direct ownership by 1% to 20,617 units (SEC Form 4)
- Director Gray William was granted 1,825 shares, increasing direct ownership by 2% to 78,546 units (SEC Form 4)
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 2,641 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 2,641 shares (SEC Form 4)
- Director Chambers James P. was granted 1,592 shares, increasing direct ownership by 2% to 67,150 units (SEC Form 4)
- Chief Executive Officer Swanson Marc was granted 59,524 shares, increasing direct ownership by 15% to 447,454 units (SEC Form 4)